Osteoporosis and bone health in HIV

Area of Science:

• Bone Metabolism and HIV Infection
• Antiretroviral Therapy Side Effects

Background:

• HIV infection is associated with various bone complications, including low bone mineral density (osteoporosis), osteonecrosis, and osteomalacia.
• Osteoporosis is the most prevalent bone pathology in HIV patients, stemming from direct/indirect effects of HIV, antiretroviral drug toxicity, or comorbidities.
• The clinical significance of osteoporosis in HIV has been debated, but fragility fractures are increasingly observed.

Purpose of the Study:

• To investigate the bone complications in patients with HIV.
• To explore the relationship between HIV, antiretroviral therapy, and bone health.
• To highlight the importance of bone mineral density screening in aging HIV populations.

Main Methods:

• Review of bone pathologies in HIV-infected individuals.
• Analysis of factors contributing to bone demineralization.
• Consideration of antiretroviral therapy's impact on bone density.

Main Results:

• Low bone mineral density and osteoporosis are common in HIV patients.
• Antiretroviral therapy initiation may accelerate short-term bone demineralization.
• Tenofovir might cause greater short-term bone density loss compared to other antivirals.

Conclusions:

• Fragility fractures are a growing concern in HIV-infected patients.
• Further research is needed to understand osteoporosis pathogenesis and management in HIV.
• Screening for low bone mineral density is increasingly vital as the HIV-infected population ages.